News
Crystal Pharmatech Triples Headquarters in Biobay, China, with More Floors and Labs
17 Aug 2013
en
This milestone further demonstrates Candoo's expertise in formulation and biopharmaceutics to achieve bioequivalence among different polymorphs and/or salts. For new chemical entities (NCE), it is useful to conduct bridging studies in late clinical stage where a more stable or favorable polymorph or salt is identified, or to show BE between clinical and commercial formulations as per regulatory requirements. For generics, this technique will help clients to speed up the development of first-to-file (Paragraph IV) products and get products launched sooner.
Subscribe to be the first to get the updates!
